Home > Business Segment > Active Pharmaceutical Ingrediants > Overview
OverviewMorepen started its bulk drug business in 1985 with the manufacturing of Ampicillin, Amoxicillin &Cloxacillin etc. by selling into domestic market.Slowly, the company shifted its focus towards International markets by making the high-tech molecules for the regulated markets like USA, Canada & EuropeA well equipped R&D centre was set up with highly qualified & skilled manpower. The multi step synthesis products like Cisapride, Loratadine,Omeprazole & Ketorolac were developed & commercialized.
The company filed its first DMF with USFDA for Loratadine in 1997 & got the USFDA approval for its plant at Masulkhana in 1999. The company has set up the state of the art facility at Baddi in the year 1998 for the manufacturing of large volumes of Bulk Drugs & its intermediates like Atorvastatin, fexofinadine and many other products for Global markets.
Later on the company filed the many DMFs & CoSin the countries like US, Canada, Europe etc. & launched many other products like Atorvastatin, Fexofinadine, Pioglitazone, Desloratadine & Montelukast in various markets globally. The company is selling large volumes of high quality advance intermediates in to the regulated markets.
Today Morepen is the leading supplier of Loratadine worldwide. It has got over 90% share in the US market. Company is the largest manufacturer of Montelukast and its intermediates.Morepen is the key player in selling its patented form of Atorvastatin Amorphous globally.
The quality & innovation has always been the focus of the company. Morepen has filed many international patents for various process improvements, polymorphs etc for products like Atorvastatin, Montelukast, Pioglitazone etc. The company has got very strong quality system & follows the latest GMP standards across all its manufacturing units.
The company has a very strong customer base which includes top generic companies worldwide and its marketing network is spread over 50 countries across all regions like Asia, Africa, Europe, Middle East & America.